Hemab Therapeutics Holdings, Inc. (COAG)

NASDAQ: COAG · Real-Time Price · USD

44.84

-4.65 (-9.40%)

Aug 28, 2026, 4:00 PM EDT - Market closed

COAG Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Selling, General & Admin	14.74	10.49	8.97
Research & Development	72.45	59.63	41.41
Operating Expenses	87.19	70.12	50.38
Operating Income	-87.19	-70.12	-50.38
Interest & Investment Income	5.24	1.97	3.74
Other Non Operating Income (Expenses)	-0.32	4.01	-1.88
Pretax Income	-83.17	-64.14	-48.52
Income Tax Expense	0.07	-0.23	0.19
Net Income	-83.24	-63.91	-48.71
Net Income to Common	-83.24	-63.91	-48.71
Net Income Growth	-	-	-
Shares Outstanding (Basic)	8	1	1
Shares Outstanding (Diluted)	8	1	1
Shares Change	-	-	-
EPS (Basic)	-10.06	-67.56	-51.49
EPS (Diluted)	-10.06	-67.56	-51.49
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-77.47	-61.49	-45.87
Free Cash Flow Per Share	-9.36	-65.00	-48.49
EBITDA	-86.89	-69.82	-50.14
D&A For EBITDA	0.3	0.3	0.25
EBIT	-87.19	-70.12	-50.38

SEC Filings: 10-K · 10-Q